Herceptin Sucks Customer Reviews and Feedback
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor-positive. It may be used by itself or together with other chemotherapy medications. Trastuzumab is given by slow injection into a vein and injection just under the skin.
Herceptin can cause several and serious side effects, according to a summary at drugs.com
"Common side effects of Herceptin include: febrile neutropenia, infection, asthenia, dizziness, fever, headache, nausea, pain, skin rash, vomiting, abdominal pain, back pain, diarrhea, flu-like symptoms, insomnia, neutropenia, pharyngitis, rhinitis, chills, and anorexia. Other side effects include: urinary tract infection, anemia, arthralgia, depression, edema, ostealgia, paresthesia, sinusitis, and tachycardia. See below for a comprehensive list of adverse effects."
teaandscones says"@benshapiro Two monoclonal antibodies, Herceptin and Perjeta, saved my life. This is absolutely game changing."
SHARE Cancer Support says"If you have HER2+ #BreastCancer and have experienced a switch from #Herceptin to a #biosimilar or presented with op… https://t.co/ttstB9e3Q9"
Kimberly Acquaviva ?️? says"RT @stales: Hey #BCSM PLEASE SHARE ---> If you have HER2+ #BreastCancer and have experienced a switch from #Herceptin to a #biosimilar o…"
Anne Marie Champagne says"@katiefar Wishing you the very best as you begin chemo. May your protocol be successful and the side effects few. H… https://t.co/H8fgvyaeow"
In The News
Canada NewsWire reports"Teva Canada Announces the Approval of HERZUMA®, a biosimilar to HERCEPTIN® for the treatment of adult patients with Early Breast Cancer, Metastatic Breast Cancer and Metastatic Gastric Cancer"
Cancer Network reports"What Is the Risk of Recurrence in HER2-Positive Breast Cancer?"
Cancer Network reports"Phase I/II Trial To Evaluate Dual HER2 Combination Therapy in HR+, HER2+ Breast Cancer"
Cancer Therapy Advisor reports"Herceptin Hylecta Approved for the Treatment of HER2-Overexpressing Breast Cancer"